Voyager Therapeutics (VYGR) 2024 Wells Fargo Healthcare Conference summary

Strategic pipeline and partnerships

• Pipeline includes four wholly owned assets and 14 partnered programs, with a new Novartis partnership announced, offering up to $8.2 billion in potential milestones.

• Three gene therapies are planned for IND filings in 2025, with clinical data expected in 2025–2026.

• Partnerships range from capsid licenses to full collaborations, providing non-dilutive revenue and milestone payments.

• The company leverages its CNS-penetrant capsid platform for broad gene therapy delivery, attracting leading partners.

• Cash reserves of $350 million are largely from partnerships, supporting internal R&D and platform expansion.

Tau program development and clinical strategy

• Lead program VY-7523, a passive anti-tau antibody, is in a phase I single-ascending dose study, with tau PET imaging results expected in 2026.

• The antibody was selected based on robust preclinical data showing 70% reduction in tau spread, outperforming failed clinical antibodies.

• A second tau program uses a vectorized siRNA approach, with an IND planned for 2026.

• The team closely monitors external tau antibody trials for read-through data to inform go/no-go decisions.

• Biomarker-driven endpoints, especially tau PET imaging, are prioritized over clinical outcomes due to variability.

SOD1 ALS and gene therapy pipeline

• The most advanced internal gene therapy targets SOD1 for ALS, using an AAV capsid and siRNA cargo, with an IND planned for mid-2025.

• The program benefits from validated biomarkers and clinical endpoints, with prior success in similar approaches.

• The company aims to demonstrate capsid efficacy in humans through clear biomarker reductions.

• Additional programs leverage the platform for CNS delivery, with ongoing toxicology studies and future milestones.